癌症生物製藥市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、應用、最終用戶、地區和競爭格局分類，2021-2031年）

全球癌症生物製劑市場預計將從 2025 年的 1,008.6 億美元成長到 2031 年的 1,528.1 億美元，複合年成長率為 7.17%。

腫瘤生物製劑是生物來源的治療藥物，例如單株抗體和疫苗，旨在透過靶向特定免疫路徑或癌細胞來治療惡性腫瘤。這項市場成長的主要驅動力是全球對精準醫療日益成長的需求，以及為確保治療創新產品線穩定而對腫瘤研究的大量資金投入。這些結構性因素代表臨床治療標準的根本轉變，而非曇花一現的趨勢。根據歐洲製藥工業協會聯合會（EFPIA）預測，到2024年，以研發為基礎的製藥業將在歐洲的研發領域投入約550億歐元，這充分體現了推動該領域發展的持續資金投入。

儘管市場成長勢頭強勁，但由於生物製藥生產和研發成本高昂，該市場仍面臨許多挑戰。這種經濟負擔造成了複雜的報銷壁壘，並迫使企業採取高定價策略，從而限制了病患的用藥機會，尤其是在對成本高度敏感的醫療體系中。這些經濟壁壘有效地限制了發展中地區的潛在市場，並對這些治療方法的全球推廣構成了重大障礙。

市場促進因素

全球各類癌症發生率的不斷上升，正成為市場擴張的主要催化劑，也因此亟需廣泛應用先進的生物療法。隨著人口老化和環境因素導致腫瘤疾病負擔日益加重，醫療系統越來越依賴生物製藥，因為生物製劑具有標靶特異性機制，與全身化療顯著不同。患者數量的激增與單株抗體和免疫療法需求的成長直接相關，促使醫療機構將這些治療方法納入標準通訊協定。根據美國癌症協會發布的《2024年癌症事實與數據》（2024年1月），預計美國2024年新增癌症病例將首次突破200萬例，這一里程碑事件凸顯了有效生物干預措施的必要性。

隨著需求的成長，生物製藥研發的快速進展以及隨之而來的監管核准激增，正在推動該領域的翻天覆地變化。生物製藥開發商優先設計具有卓越療效和安全性特徵的複雜分子，從而開啟了新型藥物活性化的時期。這種監管勢頭確保了研究突破能夠迅速轉化為實際治療方法。根據美國食品藥物管理局（FDA）於2024年1月發布的《2023年新藥核准情況》，該機構核准了55種新型療法，核准率的顯著提高促進了藥物更快進入市場。這些核准療法的商業性成功顯而易見：據默克公司稱，其生技藥品Keytruda在2023年全年的全球銷售額成長了19%，達到250億美元。

市場挑戰

生物製藥生產和研發的高昂成本是限制全球腫瘤生物製藥市場成長的主要障礙。與傳統小分子藥物不同，腫瘤生物製藥需要使用活細胞株進行高度複雜的生產流程，這需要大量的前期投資和精密的配套設施。這種沉重的經濟負擔迫使生產商採取高定價策略來回收研發投入。因此，高昂的價格在醫療體系內造成了巨大的摩擦，導致嚴格的報銷審查和有限的藥品目錄覆蓋。

這種經濟壓力直接阻礙了市場擴張，限制了患者獲得這些先進療法的機會，尤其是在對成本敏感的地區。系統性的動態進一步加劇了定價的複雜性，使患者更難負擔這些藥物。美國藥品研究與製造商協會 (PhRMA) 2024 年的一份報告發現，醫院門診機構的癌症藥物價格比醫生診所高出 1.3 到 4.3 倍。這些價格差異進一步加劇了上述報銷障礙，由於支付方和患者都在努力應對不斷上漲的醫療成本，實際上縮小了潛在市場。

市場趨勢

抗體藥物複合體(ADC) 產品線的快速擴張標誌著該領域的重大變革，其發展方向正從傳統的單株抗體轉向能夠將細胞毒性有效載荷直接遞送至癌細胞的修飾型 ADC。這一趨勢的特點是，各公司正集中投資於生產能力建設，以支持這些療法所需的複雜偶聯製程。與傳統化療相比，ADC 具有更高的療效和更低的全身毒性。主要企業正致力於保障其供應鏈，以確保這些標靶藥物的產能擴張。 2024 年 5 月，Astra Zeneca承諾投資 15 億美元在新加坡建造一座專用生產設施，以增強其 ADC 產品組合的全球供應，體現了該公司對該治療方法的高度戰略重視。

同時，人工智慧在生物製藥研發中的應用正從根本上改變蛋白質工程和標靶辨識的效率。製藥開發商正擴大與科技公司建立高價值合作關係，利用生成模型預測蛋白質結構並最佳化結合親和性，從而有效縮短新型生物製藥進入臨床試驗的時間。這些合作使得探索傳統篩檢方法無法觸及的廣大生物學領域成為可能。 2024年1月，Isomorphic Labs宣布與禮來公司達成一項價值高達17億美元的多標靶合作，旨在利用數位生物學方法發現新型態療法。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球癌症生物製藥市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（單株抗體、以細胞激素為基礎的免疫療法、癌症疫苗、CAR-T細胞療法、免疫查核點抑制劑）
  • 依應用領域（非小細胞肺癌、攝護腺癌、乳癌、急性骨髓性白血病、淋巴瘤、其他）
  • 按最終使用者（醫院/診所、門診護理中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美生物製藥市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲癌症生物製藥市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區生物製藥市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲生物製藥市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲癌症生物製藥市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球生物製藥市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cancer Biologics Market is projected to grow from USD 100.86 Billion in 2025 to USD 152.81 Billion by 2031, expanding at a CAGR of 7.17%. Cancer biologics are therapeutic agents derived from living organisms, such as monoclonal antibodies and vaccines, engineered to treat malignancies by targeting specific immune pathways or tumor cells. This market growth is primarily supported by the increasing global demand for precision medicine and substantial capital allocation toward oncology research, ensuring a steady pipeline of therapeutic innovations. These structural drivers represent a fundamental shift in clinical standards of care, rather than temporary trends. According to the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry invested an estimated €55 billion in R&D in Europe in 2024, demonstrating the sustained financial commitment fueling this sector.

Despite this strong growth trajectory, the market faces a significant challenge due to the prohibitive costs associated with biopharmaceutical manufacturing and development. This financial burden necessitates high pricing strategies that create complex reimbursement hurdles and restrict patient access, particularly in cost-sensitive healthcare systems. Such economic barriers effectively limit the addressable market in developing regions and pose a substantial impediment to the global expansion of these therapies.

Market Driver

The rising global incidence of various cancer types acts as the primary catalyst for market expansion, necessitating the widespread adoption of advanced biological therapies. As the burden of oncological diseases intensifies due to aging populations and environmental factors, healthcare systems are increasingly relying on biologics for their target-specific mechanisms, which differ significantly from systemic chemotherapy. This surge in patient volume directly correlates with a higher demand for monoclonal antibodies and immunotherapies, compelling providers to integrate these treatments into standard protocols. According to the American Cancer Society's 'Cancer Facts & Figures 2024' (January 2024), the United States is projected to witness over 2 million new cancer cases in 2024 for the first time, a milestone that highlights the critical need for effective biological interventions.

Parallel to rising demand, the rapid advancement in biological drug development and the subsequent surge in regulatory approvals are structurally reshaping the sector. Biopharmaceutical developers are prioritizing the engineering of complex molecules that offer superior efficacy and safety profiles, leading to a prolific period of commercialization for novel agents. This regulatory momentum ensures that breakthroughs in research translate quickly into available treatments. According to the U.S. Food and Drug Administration's 'Novel Drug Approvals for 2023' (January 2024), the agency approved 55 novel therapeutics, marking a significant increase in approval rates that facilitates faster market entry. The substantial commercial viability of these approved therapies is evident; according to Merck & Co. in 2024, worldwide sales for the oncology biologic Keytruda grew 19% to $25.0 billion in the full year of 2023.

Market Challenge

The prohibitive costs associated with biopharmaceutical manufacturing and development constitute a primary impediment to the growth of the Global Cancer Biologics Market. Unlike traditional small-molecule drugs, cancer biologics require highly complex production processes involving living cell lines, which necessitates substantial upfront capital and sophisticated infrastructure. This intense financial burden forces manufacturers to implement high pricing strategies to recoup research and development investments. Consequently, these elevated price points create significant friction within healthcare systems, leading to rigorous reimbursement scrutiny and restricted formulary inclusion.

This economic pressure directly hampers market expansion by limiting patient access to these advanced therapies, particularly in cost-sensitive regions. The pricing dynamics are further complicated by systemic markups that exacerbate the affordability crisis. According to the Pharmaceutical Research and Manufacturers of America in 2024, hospital outpatient facilities charged 1.3 to 4.3 times more than physician offices for cancer medicines. Such disparities in pricing structure intensify the reimbursement hurdles mentioned earlier, effectively shrinking the addressable market as payers and patients struggle to absorb the escalating costs of care.

Market Trends

The rapid expansion of Antibody-Drug Conjugate (ADC) pipelines represents a structural pivot in the sector, moving beyond standard monoclonal antibodies toward armed constructs that deliver cytotoxic payloads directly to tumor cells. This trend is characterized by intense investment in manufacturing capabilities to support the complex conjugation processes required for these therapeutics, which offer higher potency with reduced systemic toxicity compared to traditional chemotherapy. Major industry players are securing their supply chains to ensure the scalability of these targeted agents; according to AstraZeneca in May 2024, the company announced a $1.5 billion capital commitment to construct a facility in Singapore specifically designed to enhance the global supply of its ADC portfolio, reflecting the high strategic priority placed on this modality.

Concurrently, the integration of artificial intelligence into biologic drug discovery is fundamentally altering the efficiency of protein engineering and target identification. Pharmaceutical developers are increasingly forming high-value partnerships with technology firms to utilize generative models that predict protein structures and optimize binding affinities, effectively compressing the timeline for bringing novel biologics to clinical trials. These collaborations enable the exploration of vast biological spaces that were previously inaccessible through conventional screening methods. According to Isomorphic Labs in January 2024, the company established a multi-target collaboration with Eli Lilly valued at up to $1.7 billion to apply digital biology approaches for the discovery of new therapeutic agents.

Key Market Players

• Roche Holding AG
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Johnson & Johnson
• Pfizer Inc.
• AstraZeneca plc
• Eli Lilly and Company
• AbbVie Inc

Report Scope

In this report, the Global Cancer Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biologics Market, By Product

• Monoclonal Antibodies
• Cytokine-Based Immunotherapy
• Cancer Vaccines
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors

Cancer Biologics Market, By Application

• Non-small Cell Lung Cancer
• Prostate Cancer
• Breast Cancer
• Acute Myeloid Leukemia
• Lymphoma
• Others

Cancer Biologics Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Cancer Biologics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biologics Market.

Available Customizations:

Global Cancer Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biologics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Immune Checkpoint Inhibitors)
  • 5.2.2. By Application (Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cancer Biologics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Biologics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Cancer Biologics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Cancer Biologics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Cancer Biologics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Biologics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Cancer Biologics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Cancer Biologics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cancer Biologics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Cancer Biologics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Cancer Biologics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cancer Biologics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Cancer Biologics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Cancer Biologics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Cancer Biologics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Cancer Biologics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Cancer Biologics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cancer Biologics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Cancer Biologics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Cancer Biologics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Cancer Biologics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Biologics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Cancer Biologics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Cancer Biologics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cancer Biologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Roche Holding AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co., Inc.
• 15.4. Bristol-Myers Squibb Company
• 15.5. Amgen Inc.
• 15.6. Johnson & Johnson
• 15.7. Pfizer Inc.
• 15.8. AstraZeneca plc
• 15.9. Eli Lilly and Company
• 15.10. AbbVie Inc

16. Strategic Recommendations

17. About Us & Disclaimer